| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Virology II, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashi-Murayama, Tokyo 208-0011, Japan
2 Sakai Institute of Public Health, Sakai, Osaka 590-0953, Japan
3 Laboratory of Virology, Aichi Prefectural Institute of Public Health, 7-6 Nagare, Tujimachi, Kita-ku, Nagoya 462-8576, Japan
4 Saitama Institute of Public Health, Kamiokubo 639-1, Sakura-ku, Saitama 338-0824, Japan
5 Public Health and Environment Research Division, Mie Pref. Science and Technology Promotion Center, Sakuramachi 3690-1, Yokaichi, Mie 512-1211, Japan
6 Division of Virology, Chiba Prefectural Institute of Public Health, Chiba, Chiba 260-8715, Japan
7 Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1, Gakuen-Cho, Sasai, Osaka 599-8531, Japan
8 Technical Marketing Department, Denka-Seiken Co. Ltd, 1-2-2 Minami-honcho, Gosen, Niigata 959-1695, Japan
9 Department of Pathology, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashi-Murayama, Tokyo 208-0011, Japan
Correspondence
Grant S. Hansman
ghansman{at}nih.go.jp
Naokazu Takeda
ntakeda{at}nih.go.jp
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
The GenBank/EMBL/DDBJ accession numbers of the sequences reported in this paper are AB081723, AB058547, DQ093065, AB195225, DQ093062, DQ093066, DQ093063, AB195226, DQ093064, AB039780, AY237414 and DQ093067.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
; Inouye et al., 2000; Johansson et al., 2002; Kapikian et al., 1972; McEvoy et al., 1996; McIntyre et al., 2002; Russo et al., 1997). Numerous molecular epidemiological studies have revealed a global distribution of these viruses (Nakata et al., 1998; Noel et al., 1999; White et al., 2002). Transmission routes include food-borne, person-to-person contact and environmental contamination. Human NoV can be divided into two genetically distinct genogroups, GI and GII. Recently, NoV strains were subdivided into at least 14 GI and 17 GII genotypes (GI/1–14 and GII/1–17) (Kageyama et al., 2004). These viruses cannot be grown in culture and their antigenic relationships are not completely understood. Nevertheless, expression of the major capsid protein (VP1), which usually results in the formation of virus-like particles (VLPs) that are morphologically similar to the native virus, has permitted a better understanding of antigenicity in these viruses (Hansman et al., 2004). Two types of assay have been used to examine cross-reactivity among these VLPs: antibody ELISA and antigen ELISA (Gray et al., 1993; Jiang et al., 1995a, b; Kageyama et al., 2004; Kamata et al., 2005; Kobayashi et al., 2000a, b, c). The antibody ELISA is broadly reactive, but the antigen ELISA is highly specific, only detecting strains that are closely related (>95 % identity in the RNA polymerase region). However, detailed information on the cross-reactivity among many of the genetically distinct NoV strains is limited.
NoVs are small round viruses approximately 38 nm in diameter and possess a single-stranded, positive-sense RNA genome of 7·5–7·7 kb. The NoV genome contains three open reading frames (ORFs). ORF1 encodes non-structural proteins, including the RNA-dependent RNA polymerase, ORF2 encodes VP1 and ORF3 encodes a minor capsid protein (VP2) (Jiang et al., 1990). Cryo-electron microscopy (cryo-EM) and X-ray crystallography analyses of NoV VLPs have determined the shell and protruding domains (subdomains P1-1, P1-2 and P2) of the capsid protein (Prasad et al., 1999). Chen et al. (2004) also described strictly and moderately conserved amino acid residues in the capsid protein among the four genera in the family Caliciviridae.
The aim of this study was to analyse cross-reactivity among 26 different NoV VLPs in order to understand NoV genetic and antigenic relationships in more detail. An antibody ELISA using polyclonal antisera raised against the VLPs was used to determine cross-reactivities. Our results found broad-range cross-reactivities with antisera raised against a number of distinct NoV strains.
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). PCR-generated amplicons or plasmids were excised from the gel and purified by using the QIAquick Gel Extraction kit and Plasmid Purification kit (Qiagen). Nucleotide sequences were prepared with the BigDye Terminator Cycle Sequence kit (version 3.1) (Applied Biosystems) and determined by using the ABI 3100 Avant sequencer (Perkin-Elmer ABI). Nucleotide sequences were aligned with CLUSTAL_X and distances were calculated using Kimura's two-parameter method. Phylogenetic trees with bootstrap analysis from 1000 replicas were generated by the neighbour-joining method as described previously (Kageyama et al., 2004). Amino acid VP1 secondary structure predictions were made using the PSIPRED secondary structure prediction software (McGuffin et al., 2000).
Expression of VLPs.
Previously, we expressed four GI NoV strains: GI/1 (strain SeV), GI/2 (strain 258), GI/3 (strain 645) and GI/4 (strain CV), and nine GII NoV strains: GII/3 (strain 809), GII/4 (strain 104), GII/5 (strain 754), GII/6 (strain 7k), GII/7 (strain 10-25), GII/10 (strain 026), GII/12 (strains CHV and 9912-02F; in this study 9912-02F was termed Hiro) and GII/14 (strain 47) (Hansman et al., 2004; Kamata et al., 2005; Kitamoto et al., 2002; Kobayashi et al., 2000a, b, c). Dr Kim Green provided us with the Hawaii virus recombinant baculovirus GII/1 (strain HV) (Green et al., 1997). In this study, we expressed an additional 12 VLPs: GI/8 strain WUG1 (using primers G1SKF and TX30SXN; see Table 1 for primer sequences); GI/11 strain #8 (primers G1SKF and TX30SXN); GII/1 strain 485 (primers G2/F3 and G2R0); GII/2 strain Ina (primers G2Fb and G2R04); GII/3 strain 18-3 (primers G2/F3 and MVR1); GII/3 strain 1152 (primers G2F2 and G2R03); GII/3 strain 336 [primers G2/F3 and Oligo-(dT)33]; GII/3 strain Sh5 (primers G2F02 and G2R03); GII/6 strain 445 [primers G2/F3 and Oligo-(dT)33]; GII/8 strains Mc24 and U25 (primers G2SKF and TX30SXN); and GII/17 strain Alph23 (primers NAL13 and N235R). For expression of the recombinant VP1 in insect cells, all of the NoV constructs were designed to begin from the predicted VP1 AUG start codon. For six of the 12 constructs, the VP2 and poly(A) sequences were included by using either the TX30SXN or Oligo-(dT)33 reverse primers (strains WUG1, #8, 336, 445 and Mc24). One construct (strain 485) excluded the poly(A) sequence, whereas the remaining five constructs excluded both the VP2 and poly(A) sequences (strains Alph23, Sh5, 1152 and 18-3 and Ina). Four constructs that were amplified with the TX30SXN reverse primer were expressed using the Gateway expression system (strains WUG1, #8, U25 and Mc24) (Hansman et al., 2004), whilst the other eight constructs were expressed in a baculovirus expression system as described previously (Kamata et al., 2005).
|
Antibody production and ELISA.
Hyperimmune sera to newly developed VLPs were prepared in rabbits. The first subcutaneous injection was performed with purified VLPs (between 10 and 500 µg) in Freund's complete adjuvant. After 3 weeks, the animals received two or three booster injections of the same amount of VLPs in Freund's incomplete adjuvant at intervals of 1 week. The animals were bled 1 week after the last booster injection. An antibody ELISA was used to compare cross-reactivities among the VLPs. Then wells of 96-well microtitre plates (Maxisorp; Nunc) were each coated with 100 µl purified VLPs (1·0 µg ml–1 in carbonate/bicarbonate buffer, pH 9·6; Sigma) and incubated overnight at 4 °C. The wells were washed twice with PBS containing 0·1 % (v/v) Tween 20 (PBS-T) and then blocked with PBS containing 5 % (w/v) skimmed milk (PBS-SM) for 1 h at room temperature. After the wells had been washed twice with PBS-T, 100 µl twofold serially diluted hyperimmune rabbit antiserum from a starting dilution of 1 : 2000 in PBS-T-SM was added to each well and the plates were incubated for 1 h at 37 °C. The wells were washed six times with PBS-T and 100 µl horseradish peroxidase-conjugated anti-rabbit IgG (1 : 1000 dilution in PBS-T-SM) was added to each well. The plates were incubated for 1 h at 37 °C. The wells were washed six times with PBS-T and 100 µl o-phenylenediamine substrate and H2O2 was added to each well. The plates were left in the dark for 30 min at room temperature. The reaction was stopped by the addition of 50 µl 1 M H2SO4 to each well and the absorbance was measured at 492 nm. ELISA titres were expressed as the reciprocal of the highest dilution of antiserum giving a value of A492>0·2.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). Mc24 was excluded from the amino acid analysis since the full-length capsid sequence was unavailable. Nevertheless, using the partial N-terminal VP1 nucleotide sequence (GenBank accession no. AY237414), Mc24 clustered in GII/8 and was closely related to strain U25. Of the recently described NoV strains (Kageyama et al., 2004), the GI and GII genotypes used in this study represented 43 % (6/14) and 76 % (13/17), respectively. For several GII genotypes, we used two or more VLPs in order to clarify antigenicity, including GII/1 (strains HV and 485), GII/3 (strains 809, Sh5, 336, 1152 and 18-3), GII/6 (strains 7k and 445) and GII/12 (strains CHV and Hiro).
|
), despite the fact that different constructs and expression systems were used to express the recombinant VP1. The VLPs retained their morphological features, even when stored for >6 months at –20 °C (data not shown).
|
).
|
(a) shows the strong cross-reactivity of GI/11 #8 antiserum with both GII/6 7k and GII/6 445 VLPs. We found that GI/11 #8 antiserum cross-reacted with these GII/6 VLPs at titres of 102 400, which was equal to the homologous VLP titre. We also found that GII/1 HV antiserum cross-reacted strongly (i.e. equal to the homologous VLP titre) against GII/6 7k VLPs (titre 204 800) and moderately strongly (i.e. twofold lower than the homologous VLP titre) against GII/6 445 VLPs (titre 102 400) (Fig. 3b and Table 2
). We observed several antisera that cross-reacted moderately against different genotypes (i.e. fourfold lower than the homologous VLP titres). For example, GI/11 #8 antiserum cross-reacted moderately with GI/4, GI/8, GII/1, GII/2, GII/3, GII/4, GII/5, GII/7, GII/10, GII/12 and GII/17 VLPs (Fig. 3a and Table 2). GII/1 HV antiserum also cross-reacted moderately with several different genotypes, including GII/1 (strain 485), GII/3, GII/10 and GII/12 (Fig. 3b and Table 2). GII/1 485 antiserum cross-reacted moderately only with GII/1 HV VLPs; GII/6 7k antiserum cross-reacted moderately with GI/11 VLPs; GII/10 026 antiserum cross-reacted moderately with several different genotypes, including GII/1, GII/5, GII/7 and GII/12; and GII/12 CHV antiserum cross-reacted moderately with GII/1 and GII/10 VLPs (Table 2).
|
). We also observed similar weak cross-reactivities with GII/1 (strain 485), GII/2, GII/3 (all five strains), GII/4, GII/5, GII/6 (strain 445), GII/7, GII/8 (both strains), GII/14 and GII/17 antisera. For several GII genotypes, only one type of antiserum was produced, but for five GII genotypes, we produced two or more different antisera against VLPs belonging to the same genotype (Table 2). Some interesting results were observed. For example, the antigenicities of HV and 485 were considerably different, despite the fact that both strains belong to GII/1 and share approximately 94 % amino acid identity. As shown in Fig. 3(b), HV antiserum cross-reacted strongly with GII/6 VLPs, but 485 antiserum showed little cross-reactivity with these GII/6 VLPs (Table 2). This unusual cross-reactivity pattern was also observed with other antisera. For example, for GII/6, we found that 7k antiserum cross-reacted moderately with GI/11 #8 VLPs, whereas 445 antiserum cross-reacted weakly (i.e. 32-fold lower than the homologous VLP titre; Table 2). More uniquely, we found that GII/3 1152 antiserum, which was genotype-specific, had unusual antigenicity. We found that three different GII/3 antisera (strains 809, Sh5 and 18-3) cross-reacted weakly with 1152 VLPs (i.e. eightfold lower than the homologous VLP titre; Table 2 and Fig. 3c). This unusual cross-reactivity result was not evident with the other genotypes in which we produced two different antisera (i.e. GII/1, GII/6, GII/8 and GII/12; see Table 2).
Amino acid alignment and secondary structure prediction
An alignment of 25 VP1 amino acid sequences used in this study (Mc24 complete capsid was unavailable) revealed that the N-terminal region (aa 1–49), shell domain (aa 50–225) and P1-1 domain (aa 226–278) had more conserved short continuous residues than the P2 domain (aa 279–405), P1-2 domain (aa 406–520) and C-terminal region (Fig. 4). These continuous residues may be the reason for the cross-reactivity among different genotypes, in particular, the strong cross-reactivity of #8 antiserum against GII/6 VLPs (Fig. 3a). However, this does not explain why GII/3 1152 VLPs cross-reacted weakly with GII/3 809, Sh5 and 18-3 antisera (i.e. eightfold lower than the homologous VLP titre) and moderately against GII/3 336 antiserum (i.e. fourfold lower than the homologous VLP titre). An amino acid alignment of these five GII/3 VP1 sequences showed no unusual insertions, deletions or recombination sites; in fact, the shell domain was highly conserved among the GII/3 sequences (data not shown). However, the 1152 VP1 sequence had three unique amino acid residues (Thr-285, Ile-372 and Ser-508) when compared with the other four GII/3 VP1 sequences. The first two residues were located in the outermost region of the P2 domain, whilst the third residue was located within the P1 domain (data not shown). We used the PSIPRED secondary structure prediction software (McGuffin et al., 2000) to compare the five GII/3 VP1 structures. We found that the predicted VP1 structures for 809, Sh5, 18-3 and 336 had a helix between residues 219 and 237, whereas this helix structure was absent for 1152 (Fig 5). These data suggested that the helix structure may play an important role in influencing the cross-reactivity among the GII/3 VLPs and antisera.
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
, we also observed strong, moderately strong and moderate cross-reactivities among different genotypes (i.e. equal to the homologous VLP titre and to twofold and fourfold dilutions, respectively). For example, GI/11 antiserum had a broad range of cross-reactivities, detecting two GI genotypes (GI/4 and GI/8) and 10 GII genotypes (GII/1–7, GII/10, GII/12 and GII/17); GII/1 antiserum (strain HV) had a broad range of cross-reactivities, detecting four GII genotypes (GII/3, GII/6, GII/10 and GII/12); GII/10 antisera also had a broad range of cross-reactivities, detecting four GII genotypes (GII/1, GII/5, GII/7 and GII/12); GII/6 antiserum detected GI/11 VLPs; and GII/12 antiserum (strain CHV) detected GII/1 and GII/10 VLPs.
|
), this is the first report of a GI (strain #8) polyclonal antiserum cross-reacting strongly with other GII genotypes and the first report of a GII (strain HV) polyclonal antiserum cross-reacting strongly with other GII genotypes (Jiang et al., 2002; Kamata et al., 2005; Kitamoto et al., 2002). These broad-range cross-reactivities may be due to unfolded VLPs on the microtitre plates at the high pH used (carbonate/bicarbonate buffer, pH 9·6) (White et al., 1997). However, we have not found such broad-range cross-reactivities in any of our other studies (Kamata et al., 2005). Conserved continuous residues in the shell and/or P1-1 domains may be the reason for these cross-reactivities against different genotypes (Fig. 4 and Table 2). However, we found that several antisera were genotype-specific, indicating that VLPs have unique epitopes.
Interestingly, we found that four types of GII/3 antisera (strains 809, Sh5, 18-3 and 336) cross-reacted moderately to weakly against GII/3 1152 VLPs (i.e. up to eightfold lower than the homologous VLP titre; Table 2). Amino acid alignments of these five GII/3 sequences revealed that 1152 had three unique amino acid residues compared with the other four GII/3 sequences (Thr-285, Ile-372 and Ser-508), two of which were located within the P2 domain (Thr-285 and Ile-372). Amino acid secondary structure predictions made using the PSIPRED secondary structural prediction software revealed that the VP1 secondary structures for 809, Sh5, 18-3 and 336 had a helix structure between residues 219 and 237; this helix structure was absent for 1152 (Fig. 5). This helix structure may, in part, influence the cross-reactivity among the GII/3 VLPs (i.e. without the helix structure); GII/3 1152 VLPs cross-reacted weakly with the other four GII/3 antisera. This suggestion may also explain NoV virulence in which some strains appear to infect a certain population over an extended period of time (Dingle, 2004; Noel et al., 1999). In a recent report, single amino acid changes were suggested to represent a possible way for the virus to evade the host immunity (Dingle, 2004). In addition, one report suggested that a change in VP1 secondary structure (i.e. the disappearance of a helix structure) was responsible for a chronic NoV infection in an immunocompromised patient for over 2 years (Nilsson et al., 2003).
Almost half of our constructs (strains SeV, 645, CV, HV, Ina, 809, Sh5, 18-3, 1152, 104, 754, CHV and Alph23) did not include the ORF3 sequence, which encodes a minor capsid protein (VP2) thought to increase the stability of NoV VLPs and may function in RNA genome packaging (Bertolotti-Ciarlet et al., 2003). For rabbit haemorrhagic disease virus, VP2 is essential for the production of infectious virus (Sosnovtsev & Green, 2000). Nevertheless, we found that all constructs with or without ORF3 sequences expressed VLPs that were morphologically similar to native NoV (Fig. 2). Further studies are needed to determine whether VP2 has some influence on antigenicity.
In conclusion, this cross-reactivity study represents the most extensive undertaken for any genera in the family Caliciviridae. Since human NoV strains cannot be propagated in cell culture systems and human serological studies have found that VLPs and native virions share similar antigenic properties, VLPs have been used to understand antigenic relationships in more detail. Further studies, such as high-resolution structural analysis of other NoV genotypes and antigenic mapping, are needed in order to explain the complex NoV antigenicity, as previously suggested (Chen et al., 2004). Finally, the results and reagents from this study can be used to design detection systems capable of detecting a broad-range of genotypes in clinical specimens; in particular, GI/11 antisera may be capable of detecting at least 32 % (12/37) of the recently described NoV genotypes (Kageyama et al., 2004).
|
ACKNOWLEDGEMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Beuret, C., Baumgartner, A. & Schluep, J. (2003). Virus-contaminated oysters: a three-month monitoring of oysters imported to Switzerland. Appl Environ Microbiol 69, 2292–2297.
Chen, R., Neill, J. D., Noel, J. S., Hutson, A. M., Glass, R. I., Estes, M. K. & Prasad, B. V. V. (2004). Inter- and intragenus structural variations in caliciviruses and their functional implications. J Virol 78, 6469–6479.
Dingle, K. E. (2004). Mutation in a Lordsdale norovirus epidemic strain as a potential indicator of transmission routes. J Clin Microbiol 42, 3950–3957.
Gray, J. J., Jiang, X., Morgan-Capner, P., Desselberger, U. & Estes, M. K. (1993). Prevalence of antibodies to Norwalk virus in England: detection by enzyme-linked immunosorbent assay using baculovirus-expressed Norwalk virus capsid antigen. J Clin Microbiol 31, 1022–1025.
Green, K. Y., Kapikian, A. Z., Valdesuso, J., Sosnovtsev, S., Treanor, J. J. & Lew, J. F. (1997). Expression and self-assembly of recombinant capsid protein from the antigenically distinct Hawaii human calicivirus. J Clin Microbiol 35, 1909–1914.[Abstract]
Hansman, G. S., Doan, L. T. P., Kguyen, T. A. & 9 other authors (2004). Detection of norovirus and sapovirus infection among children with gastroenteritis in Ho Chi Minh City, Vietnam. Arch Virol 149, 1673–1688.[Medline]
Inouye, S., Yamashita, K., Yamadera, S., Yoshikawa, M., Kato, N. & Okabe, N. (2000). Surveillance of viral gastroenteritis in Japan: pediatric cases and outbreak incidents. J Infect Dis 181, S270–S274.
Jiang, X., Graham, D. Y., Wang, K. N. & Estes, M. K. (1990). Norwalk virus genome cloning and characterization. Science 250, 1580–1583.
Jiang, X., Cubitt, D., Hu, J., Dai, X., Treanor, J., Matson, D. O. & Pickering, L. K. (1995a). Development of an ELISA to detect MX virus, a human calicivirus in the Snow Mountain Agent genogroup. J Gen Virol 76, 2739–2747.
Jiang, X., Wang, J. & Estes, M. K. (1995b). Characterization of SRSVs using RT-PCR and a new antigen ELISA. Arch Virol 140, 363–374.[CrossRef][Medline]
Jiang, X., Wilton, N., Zhong, W. M. & 11 other authors (2000). Diagnosis of human caliciviruses by use of enzyme immunoassays. J Infect Dis 181, S349–S359.
Jiang, X., Zhong, W. M., Farkas, T., Huang, P. W., Wilton, N., Barrett, E., Fulton, D., Morrow, R. & Matson, D. O. (2002). Baculovirus expression and antigenic characterization of the capsid proteins of three Norwalk-like viruses. Arch Virol 147, 119–130.[CrossRef][Medline]
Johansson, P. J. H., Torvén, M., Hammarlund, A.-C., Björne, U., Hedlund, K.-O. & Svensson, L. (2002). Food-borne outbreak of gastroenteritis associated with genogroup I calicivirus. J Clin Microbiol 40, 794–798.
Kageyama, T., Shinohara, M., Uchida, K. & 7 other authors (2004). Coexistence of multiple genotypes, including newly identified genotypes, in outbreaks of gastroenteritis due to Norovirus in Japan. J Clin Microbiol 42, 2988–2995.
Kamata, K., Shinozaki, K., Okada, M. & 10 other authors (2005). Expression and antigenicity of virus-like particles of norovirus and their application for detection of noroviruses in stool samples. J Med Virol 76, 129–136.[Medline]
Kapikian, A. Z., Wyatt, R. G., Dolin, R., Thornhill, T. S., Kalica, A. R. & Chanock, R. M. (1972). Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol 10, 1075–1081.
Katayama, K., Shirato-Horikoshi, H., Kojima, S. & 9 other authors (2002). Phylogenetic analysis of the complete genome of 18 Norwalk-like viruses. Virology 299, 225–239.[CrossRef][Medline]
Kitamoto, N., Tanaka, T., Natori, K., Takeda, N., Nakata, S., Jiang, X. & Estes, M. K. (2002). Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP. J Clin Microbiol 40, 2459–2465.
Kobayashi, S., Sakae, K., Natori, K., Takeda, N., Miyamura, T. & Suzuki, Y. (2000a). Serotype-specific antigen ELISA for detection of Chiba virus in stools. J Med Virol 62, 233–238.[CrossRef][Medline]
Kobayashi, S., Sakae, K., Suzuki, Y., Ishiko, H., Kamata, K., Suzuki, K., Natori, K., Miyamura, T. & Takeda, N. (2000b). Expression of recombinant capsid proteins of Chitta virus, a genogroup II Norwalk virus, and development of an ELISA to detect the viral antigen. Microbiol Immunol 44, 687–693.[Medline]
Kobayashi, S., Sakae, K., Suzuki, Y. & 8 other authors (2000c). Molecular cloning, expression, and antigenicity of Seto virus belonging to genogroup I Norwalk-like viruses. J Clin Microbiol 38, 3492–3494.
McEvoy, M., Blake, W., Brown, D., Green, J. & Cartwright, R. (1996). An outbreak of viral gastroenteritis on a cruise ship. Commun Dis Rep CDR Rev 6, R188–R192.[Medline]
McGuffin, L. J., Bryson, K. & Jones, D. T. (2000). The PSIPRED protein structure prediction server. Bioinformatics 16, 404–405.
McIntyre, L., Vallaster, L., Kurzac, C., Fung, J., McNabb, A., Lee, M.-K., Daly, P., Petric, M. & Isaac-Renton, J. (2002). Gastrointestinal outbreaks associated with Norwalk virus in restaurants in Vancouver, British Columbia. Can Commun Dis Rep 28, 197–203.[Medline]
Nakata, S., Honma, S., Numata, K. & 8 other authors (1998). Prevalence of human calicivirus infections in Kenya as determined by enzyme immunoassays for three genogroups of the virus. J Clin Microbiol 36, 3160–3163.
Nilsson, M., Hedlund, K.-O., Thorhagen, M., Larson, G., Johansen, K., Ekspong, A. & Svensson, L. (2003). Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype. J Virol 77, 13117–13124.
Noel, J. S., Fankhauser, R. L., Ando, T., Monroe, S. S. & Glass, R. I. (1999). Identification of a distinct common strain of "Norwalk-like viruses" having a global distribution. J Infect Dis 179, 1334–1344.[CrossRef][Medline]
Prasad, B. V. V., Hardy, M. E., Dokland, T., Bella, J., Rossmann, M. G. & Estes, M. K. (1999). X-ray crystallographic structure of the Norwalk virus capsid. Science 286, 287–290.
Russo, P. L., Spelman, D. W., Harrington, G. A., Jenney, A. W., Gunesekere, I. C., Wright, P. J., Doultree, J. C. & Marshall, J. A. (1997). Hospital outbreak of Norwalk-like virus. Infect Control Hosp Epidemiol 18, 576–579.[Medline]
Sosnovtsev, S. V. & Green, K. Y. (2000). Identification and genomic mapping of the ORF3 and VPg proteins in feline calicivirus virions. Virology 277, 193–203.[CrossRef][Medline]
White, L. J., Hardy, M. E. & Estes, M. K. (1997). Biochemical characterization of a smaller form of recombinant Norwalk virus capsids assembled in insect cells. J Virol 71, 8066–8072.[Abstract]
White, P. A., Hansman, G. S., Li, A., Dable, J., Isaacs, M., Ferson, M., McIver, C. J. & Rawlinson, W. D. (2002). Norwalk-like virus 95/96-US strain is a major cause of gastroenteritis outbreaks in Australia. J Med Virol 68, 113–118.[CrossRef][Medline]
Received 15 September 2005;
accepted 19 December 2005.
This article has been cited by other articles:
|
|
 |
|
  M. Iwai, S. Hasegawa, M. Obara, K. Nakamura, E. Horimoto, T. Takizawa, T. Kurata, S.-i. Sogen, and K. Shiraki Continuous Presence of Noroviruses and Sapoviruses in Raw Sewage Reflects Infections among Inhabitants of Toyama, Japan (2006 to 2008) Appl. Envir. Microbiol., March 1, 2009; 75(5): 1264 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Someya, N. Takeda, and T. Wakita Saturation Mutagenesis reveals that GLU54 of Norovirus 3C-like Protease is not Essential for the Proteolytic Activity J. Biochem., December 1, 2008; 144(6): 771 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Motomura, T. Oka, M. Yokoyama, H. Nakamura, H. Mori, H. Ode, G. S. Hansman, K. Katayama, T. Kanda, T. Tanaka, et al. Identification of Monomorphic and Divergent Haplotypes in the 2006-2007 Norovirus GII/4 Epidemic Population by Genomewide Tracing of Evolutionary History J. Virol., November 15, 2008; 82(22): 11247 - 11262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shirato, S. Ogawa, H. Ito, T. Sato, A. Kameyama, H. Narimatsu, Z. Xiaofan, T. Miyamura, T. Wakita, K. Ishii, et al. Noroviruses Distinguish between Type 1 and Type 2 Histo-Blood Group Antigens for Binding J. Virol., November 1, 2008; 82(21): 10756 - 10767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-C. Li, P. D. Scotti, T. Miyamura, and N. Takeda Latent Infection of a New Alphanodavirus in an Insect Cell Line J. Virol., October 15, 2007; 81(20): 10890 - 10896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Thackray, C. E. Wobus, K. A. Chachu, B. Liu, E. R. Alegre, K. S. Henderson, S. T. Kelley, and H. W. Virgin IV Murine Noroviruses Comprising a Single Genogroup Exhibit Biological Diversity despite Limited Sequence Divergence J. Virol., October 1, 2007; 81(19): 10460 - 10473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Siebenga, H. Vennema, B. Renckens, E. de Bruin, B. van der Veer, R. J. Siezen, and M. Koopmans Epochal Evolution of GGII.4 Norovirus Capsid Proteins from 1995 to 2006 J. Virol., September 15, 2007; 81(18): 9932 - 9941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Hansman, H. Saito, C. Shibata, S. Ishizuka, M. Oseto, T. Oka, and N. Takeda Outbreak of Gastroenteritis Due to Sapovirus J. Clin. Microbiol., April 1, 2007; 45(4): 1347 - 1349. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
-strand by an arrow and a coil by a line. The third line also shows the predicted secondary structure (Pred), where H represents a helix, E a